Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Shlien and colleagues report on 300 patients from the SickKids Cancer Sequencing program and identify clinically actionable variants in 56% of the patients by profiling somatic and germline data at multiple clinical time points.
Gulhati et al. demonstrate therapeutic efficacy for combinatorial administration of 41BB agonist, LAG3 antagonist and a CXCR1/2 inhibitor in murine pancreatic cancer models, resulting in a remodeled tumor microenvironment.
Silva and colleagues develop a network-based HDAC6 score which could predict sensitivity to the HDAC6 inhibitor ricolinstat in preclinical models, as well as patients with HR+/HER2− breast cancer that received ricolinstat in a phase 1b clinical trial.
Lasry and Nadorp et al. use single-cell RNA sequencing and CITE sequencing to reveal inflammatory gene expression in a subset of pediatric and adult patients with acute myeloid leukemia that associates with changes in the immune microenvironment and generate an inflammatory score with prognostic potential.
Oh and colleagues demonstrate that the DUSP6–RSK1 axis is involved in the transformation of myeloproliferative neoplasms to secondary acute myeloid leukemia and that DUSP6 mediates the response to JAK2 inhibition.
Müller-Tidow and colleagues perform a randomized clinical trial and show that administration of convalescent plasma improves COVID-19 outcome in patients with cancer who are unable to generate an adequate immune response.
Keppler and colleagues show that individuals with hematological cancers rapidly develop potent infection-neutralizing antibodies and a robust T cell response against several SARS-CoV-2 variants of concern in response to mRNA vaccination.
Mazzone and colleagues identify the bicarbonate transporter SLC4A4 as highly abundant in epithelial duct cells in pancreatic cancer and show that its inhibition mitigates acidosis in the tumor, thereby alleviating immune suppression and overcoming immunotherapy resistance.
Earnest-Noble et al. report the opposing regulation during breast cancer metastasis of two isoleucyl tRNAs that decode synonymous codons, leading to divergent regulation of metastatic growth by influencing translation of growth-regulating genes.
Shahbandi et al. find that cancer cells that survive chemotherapy (CT) activate two immune-modulatory programs characterized by IFN response genes and CD274 or p53 signaling and CD80 expression. Targeting these pathways enhances the CT response.
Spurr et al. identify high pretreatment aneuploidy score as a potential biomarker in patients with NSCLC who benefit from concurrent radiation and immune checkpoint inhibition, in immunogenomic analysis of data from a phase I clinical trial.
Karam and colleagues report a phase I/Ib trial in patients with HNSCC treated with neoadjuvant SBRT and anti-PD-L1, and perform high-dimensional analyses of immune correlates of response in the tissue microenvironment and peripheral blood.
Bernards and colleagues identify cFLIP as a common dependency of cancer cells by conferring protection from senolytic-induced cell death. They nominate combination of DR5 activation and cFLIP suppression for enhanced killing of senescent cancer cells.
Nishiga and colleagues show therapeutic efficacy for a combination of radiotherapy and CD47 blockade, which also elicits an abscopal effect mediated by macrophages migrating into non-irradiated tumor sites and phagocytosing cancer cells.
Halbrook et al. report two metabolic subgroups of pancreatic ductal adenocarcinoma cells defined by differential integrated stress response and asparagine production that permit symbiosis and phenformin resistance.
Yu and colleagues develop a OV-Cmab-CCL5 oncolytic virus that targets EGFR+ glioblastoma cells and releases CCL5 into the tumor microenvironment, which promotes anti-tumor immune responses and prolonged survival in preclinical GBM models.
Barriga et al. develop MACHETE, a genome engineering strategy enabling the flexible modeling of megabase-sized deletions and show that the concomitant loss of the interferon cluster with CDKN2A/B deletions on 9p21.3 enhances immune evasion.
Yofe et al. demonstrate that FcγR engagement early after anti-CTLA-4 blockade induces a rapid remodeling of innate immunity and activation of type I interferon signaling, which are crucial for successful anti-CTLA-4 therapy.
Shao et al. show that EGFR signaling increases expression of the complement regulatory proteins CD55 and CD59, suppressing the complement. This is mediated via a sponging lncRNA and interfering with the axis synergizes with immunotherapy.
Hung and colleagues show that ALK-mediated CDK9 activation increases homologous recombination repair and PARP inhibition resistance and propose combinatorial inhibition of ALK and PARP as therapeutically beneficial for treatment-resistant tumors.